Indication: For the prophylaxis of bipolar affective disorders and episodes of major depression; for certain cases of acute depression, e.g. therapy resistance and/or contraindication for antidepressive drugs; as therapy for manic episodes; and for the prophylaxis of manic-depressive diseases, endogenous depressions, manic and hypomanic conditions (if necessary in combination with neuroleptic drugs), and certain acute depressions (therapy resistance, contraindication for standard therapy, etc.).
Brand name: Camcolit (Norgine), Liskonum (GSK), Priadel (Sanofi-Synthelabo), Hypnorex retard (Sanofi-Synthelabo GmbH), Lithium-SB/Lithium-SB retard (GSK).
Regulatory status: Approved.
Launch date: 7 November 2003, 22 February 1995, and 2 August 1994.